CytoSorb^{® –} is the only specifically approved extracorporeal cytokine adsorber in the European Union, designed to reduce the “fuel to the fire” of deadly inflammation often seen in critically-ill patients in the intensive care unit (ICU) and those undergoing complex open heart surgery. Examples of this “fuel” include: excessive cytokines, bacterial toxins, activated complement, plasma free hemoglobin, bilirubin, and a host of other inflammatory mediators.

In doing so, CytoSorb® targets the prevention or treatment of one of the most dreaded consequences of an uncontrolled, systemic inflammatory response: the failure of vital organs such as the brain, heart, kidneys and lungs.

CytoSorb® is compatible with standard hemodialysis machines, continuous renal replacement therapy (CRRT) machines, heart-lung machines, most extracorporeal membrane oxygenation (ECMO) machines, and other blood pumps found in most hospitals.